Literature DB >> 12782602

Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system.

Virote Sriuranpong1, Jong In Park, Panomwat Amornphimoltham, Vyomesh Patel, Barry D Nelkin, J Silvio Gutkind.   

Abstract

The aberrant growth of head and neck squamous cell carcinoma (HNSCC) is often associated with the constitutive activation of signal-transducer-and-activator-of-transcription-3 (STAT3), which is believed to result from the persistent stimulation of EGF receptors that are highly expressed in squamous cell carcinoma (SCC) cells. To investigate the mechanism underlying STAT3 deregulation in HNSCC, we examined the interplay of the STAT3 and epidermal growth factor receptor (EGFR) signaling pathways using a panel of HNSCC cell lines. Although STAT3 was active in most HNSCC cell lines, only 3 of 10 HNSCC cell lines were moderately to strongly positive for activated EGFR. Even in the EGFR-positive cell lines, STAT3 activation was not dependent on EGFR activation, as STAT3 tyrosine phosphorylation levels persisted after treatment with AG1478, a chemical inhibitor of EGFR activity. Furthermore, we found that conditioned medium harvested from HNSCC cells could induce STAT3 tyrosine phosphorylation in immortalized keratinocytes regardless of the status of EGFR signaling. In contrast, blocking the cytokine gp130 coreceptor abolished STAT3 tyrosine phosphorylation in HNSCC cells and that induced by the conditioned medium. Immunodepletion studies suggested interleukin 6 (IL6) as the major autocrine/paracrine factor for STAT3 activation, which coincided with high levels of secretion of IL6 into the culture medium by these cancer cells. Treatment with a specific inhibitor of Janus kinase, AG490, in HNSCC cells led to a reduction of active STAT3 and caused significant growth retardation and apoptosis. Thus, constitutive activation of STAT3 in HNSCC may use an autocrine/paracrine-activating loop mediated by IL6 and other cytokines acting through the gp130 receptor family, which may confer both proliferative and survival potential in this malignancy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12782602

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  116 in total

Review 1.  Molecular parameters of head and neck cancer metastasis.

Authors:  Sanjay L Bhave; Theodoras N Teknos; Quintin Pan
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2011       Impact factor: 1.807

2.  HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines.

Authors:  Paul A Johnston; Malabika Sen; Yun Hua; Daniel P Camarco; Tong Ying Shun; John S Lazo; Gabriela Mustata Wilson; Lynn O Resnick; Matthew G LaPorte; Peter Wipf; Donna M Huryn; Jennifer R Grandis
Journal:  Assay Drug Dev Technol       Date:  2015-09       Impact factor: 1.738

3.  Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells.

Authors:  Christiane Stuhlmann-Laeisz; Sigrid Lang; Athena Chalaris; Paliga Krzysztof; Sudarman Enge; Jutta Eichler; Ursula Klingmüller; Michael Samuel; Matthias Ernst; Stefan Rose-John; Jürgen Scheller
Journal:  Mol Biol Cell       Date:  2006-04-19       Impact factor: 4.138

4.  Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma.

Authors:  Marta Moral; Carmen Segrelles; M Fernanda Lara; Ana Belén Martínez-Cruz; Corina Lorz; Mirentxu Santos; Ramón García-Escudero; Jerry Lu; Kaoru Kiguchi; Agueda Buitrago; Clotilde Costa; Cristina Saiz; Jose L Rodriguez-Peralto; Francisco J Martinez-Tello; Maria Rodriguez-Pinilla; Montserrat Sanchez-Cespedes; Marina Garín; Teresa Grande; Ana Bravo; John DiGiovanni; Jesús M Paramio
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

5.  Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery.

Authors:  Ashwin A Bhirde; Vyomesh Patel; Julie Gavard; Guofeng Zhang; Alioscka A Sousa; Andrius Masedunskas; Richard D Leapman; Roberto Weigert; J Silvio Gutkind; James F Rusling
Journal:  ACS Nano       Date:  2009-02-24       Impact factor: 15.881

6.  Serpin B3/B4, activated by STAT3, promote survival of squamous carcinoma cells.

Authors:  Simi T Ahmed; James E Darnell
Journal:  Biochem Biophys Res Commun       Date:  2008-12-12       Impact factor: 3.575

7.  EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.

Authors:  Elise V M Fletcher; Laurie Love-Homan; Arya Sobhakumari; Charlotte R Feddersen; Adam T Koch; Apollina Goel; Andrean L Simons
Journal:  Mol Cancer Res       Date:  2013-09-18       Impact factor: 5.852

Review 8.  The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.

Authors:  Ranee Mehra; Roger B Cohen; Barbara A Burtness
Journal:  Clin Adv Hematol Oncol       Date:  2008-10

9.  Squamous carcinoma cells influence monocyte phenotype and suppress lipopolysaccharide-induced TNF-alpha in monocytes.

Authors:  Aroonwan Lam-ubol; Dustin Hopkin; Elena M Letuchy; Zoya B Kurago
Journal:  Inflammation       Date:  2010-08       Impact factor: 4.092

10.  Lipopolysaccharide-squamous cell carcinoma-monocyte interactions induce cancer-supporting factors leading to rapid STAT3 activation.

Authors:  Zoya B Kurago; Aroonwan Lam-ubol; Anton Stetsenko; Chris De La Mater; Yiyi Chen; Deborah V Dawson
Journal:  Head Neck Pathol       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.